Key clinical point: Appropriate rosacea treatment depends on specific clinical symptoms rather than distinct subtypes.

Major finding: Overlapping symptoms require particular attention to each patient’s phenotype as opposed to broad categorization into subtypes.

Study details: The recommendations by 27 clinical experts in dermatology, laser therapy, skin care, and ophthalmology are based on the most current evidence on rosacea management.

Disclosures: Funding was provided by the National Rosacea Society, which receives funding from patients and corporations that include Aclaris Therapeutics, Allergan, Bayer, Cutanea Life Sciences, and Galderma Laboratories. Dr. Thiboutot consults for Galderma. Six of the other nine coauthors have financial links to industry through advisory boards, consulting, or research funding.